Sab biotherapeutics announces q1 2024 financial results and provides company updates

Miami, may 20, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today reported financial results for the first quarter ended march 31, 2024, and provided a company update. “as we work towards upcoming sab-142 milestones, i remain enthusiastic about our ongoing progress executing a focused corporate strategy centered on immunotherapy, t1d,” notes sab chairman and ceo samuel j.
SABS Ratings Summary
SABS Quant Ranking